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The NF-kB family of transcription factors is up-regulated in inflammation and different cancers. Recent data
described heterozygous deletions of the NF-kB Inhibitor alpha gene (NFKBIA) in about 20% of glioblastomas (GBM):
deletions were mutually exclusive with epidermal growth factor receptor (EGFR) amplification, a frequent event in
GBM. We assessed the status of NFKBIA and EGFR in 69 primary GBMs and in corresponding neurospheres (NS).
NFKBIA deletion was investigated by the copy number variation assay (CNV); EGFR amplification by CNV ratio with
HGF; expression of EGFR and EGFRvIII by quantitative PCR or ReverseTranscriptase PCR. Heterozygous deletions of
NFKBIA were present in 3 of 69 primary GBMs and, surprisingly, in 30 of 69 NS. EGFR amplification was detected in
36 GBMs: in corresponding NS, amplification was lost in 13 cases and reduced in 23 (10 vs 47 folds in NS vs primary
tumors; p < 0.001). The CNV assay was validated investigating HPRT1 on chromosome X in females and males.
Results of array-CGH performed on 3 primary GBMs and 1 NS line were compatible with the CNV assay. NS cells
with NFKBIA deletion had increased nuclear activity of p65 (RelA) and increased expression of the NF-kB target IL-6.
In absence of EGF in the medium, EGFR amplification was more conserved and NFKBIA deletion less frequent point
to a low frequency of NFKBIA deletions in GBM and suggest that EGF in the culture medium of NS may affect
frequency not only of EGFR amplifications but also of NFKBIA deletions.Introduction
Glioblastoma multiforme (GBM) is the highest grade gli-
oma, according to World Health Organization classifica-
tion, and has an annual incidence of 5 cases per 100,000
people [1,2]. In recent years, a huge effort was made to
achieve a more thorough characterization of genetic and
molecular signatures of GBM, facilitating the identifica-
tion of new molecular targets and leading to a classifica-
tion in four molecular subtypes: classical, mesenchymal,
proneural and neural [3,4]. The classical subtype is
mostly characterized by loss of chromosome 10 and
amplification of the epidermal growth factor receptor
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reproduction in any medium, provided the orIn the past years several studies have pointed to the
importance of EGFR and NF-kB pathways in formation,
growth and relapse of many tumor types, including
GBM, and recent evidence suggests a cross-talk between
these pathways [5-8].
NF-kB is a heterodimeric transcription factor formed
by a family of Rel proteins, sharing a common N-
terminal DNA binding region (RelA/p65, RelB and
RelC), and by proteins that contain an ankyrin domain
(p50, p100). NF-kB complexes are maintained inactive
in the cytoplasm through interaction with their inhibi-
tor IkBα, encoded by the NFKBIA gene located on
chromosome 14q13.2. Most stimuli activate this path-
way through phosphorylation of the IKK complex,
which in turn phosphorylates IkBα, leading the inhibi-
tor to degradation and allowing nuclear translocation
of NF-kB. In the nucleus, NF-kB regulates the tran-
scription of several genes involved in proliferation,
survival, tissue invasion, inhibition of apoptosis andLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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kines [9]. Two pathways of NF-kB activation have been
described: canonical and non-canonical, involving dif-
ferent types of kinases (STAT3, PI3K/Akt, MAPK) and
distinct heterodimers (p65/p50; p100/RelB) [10].
EGFR is mostly involved in proliferation and is
expressed at high levels in many types of cancers, in-
cluding glioblastoma [11]. EGFR is a tyrosine-kinase
receptor, which signals through two main pathways:
Ras/MAPK kinases and PI3K/Akt/mTOR kinases. Its
gene, located on chromosome 7p11.2, is amplified in ~40%
GBMs, forming typical double-minutes, auto-replicative
chromosomes: this amplification is distinguished from
polisomy of chromosome 7, a frequent event in GBM.
EGFR gene can be also mutated: in particular, the deletion
of exons 2-7 generates a constitutively activated form,
called EGFRvIII, which lacks of the extracellular domain
and is not able to bind the EGF ligand and to internalize,
leading to low-level continuous signalling. This mutant is
present in ~ 50% of GBM with EGFR amplification [12,13]
and reciprocal interactions between EGFR and EGFRvIII
have been reported recently [14]. Another type of EGFR
amplification was observed in ~ 30% of GBM with extra
copies of the gene inserted in different loci of chromosome
7; in this form of amplification the number of gene copies
is small and the percentage of amplified cells is less than
15% [15].
Several studies have pointed to a relationship between
EGFR and NFKB pathways mostly through activation of
PI3K/Akt/mTOR signalling [7,16,17]. Relevant interac-
tions between EGFR, the most important oncogene in
GBMs, and NF-kB have been first proposed in breast
cancer [16]. In GBMs association between SHP-2 and
Grb2-associated binder 1 (Gab1) was identified as a critical
step in the pathway linking EGFR to NF-kB activation [18].
One report, in particular, proposed a correlation between
NF-kB and EGFR status at the genetic level, describing the
heterozygous deletion of NFKBIA in 20% of primary GBMs
in mutual exclusion with EGFR amplification [19]. How-
ever, in a previous studiy based on single nucleotide poly-
morphism DNA microarray analysis of GBM we did not
find evidence of chromosomal imbalance on chromosome
14q13.2, where NFKBIA is mapping [20].
We decided to investigate the NFKBIA status in rela-
tionship to EGFR in primary GBM and in GBM stem-
like cells, a highly tumorigenic subpopulation exploit-
ing stem cell programs for glioma perpetuation [21].
These cells are traditionally grown as neurospheres
(NS) in the presence of EGF and bFGF, mimicking the
growth of normal neural stem cells [22,23]. Surpris-
ingly, we found that NFKBIA deletion is rare in primary
tumors, but becomes frequent in GBM NS, an event
that seems to be affected by the presence of EGF in the
culture medium.Material and methods
Tumor specimens and cell cultures
The research work described in this paper is in compli-
ance with the Helsinki Declaration. Patients considered in
this study had signed an informed consent, defined and
approved by the Quality Office of the Istituto Neurologico
Besta (CI 25), agreeing on the use of part of their tumor
specimens for research purposes. Human glioblastoma
specimens, diagnosed as grade IV gliomas according to
WHO criteria, were snap frozen or paraffin-embedded
after surgery. Neurospheres (here equivalent to glioblast-
oma stem-like cells) were derived by mechanical dissoci-
ation and digestion of tumor specimens with collagenase
type I (Invitrogen, Life technologies, Foster City CA,
USA). Single cell suspensions were plated at clonal density
(50 cells/μl) in standard medium containing: DMEM/F-12
(GIBCO, Life Technologies, Foster City CA, USA), 2 mM
glutamine (Sigma Aldrich, St.Louis MO, USA), penicillin-
streptomycin (1:100, EuroClone, Italy), B-27 supplement
(1:50, GIBCO, Life technologies, Foster City CA, USA),
human recombinant fibroblast growth factor 2 (bFGF
20 ng/ml; Tebu Bio, France) and epidermal growth factor
(EGF, 20 ng/ml; Tebu Bio, France).
Nucleic acid extraction
Total DNA was extracted using QIAamp DSP DNA
Blood Mini Kit (Qiagen, Hilden, Germany) for periph-
eral blood and PureLink™ Pro 96 Genomic DNA Purifi-
cation Kit (Invitrogen, Life technologies, Foster City CA,
USA) for paraffin-embedded tumors according to proto-
cols of the manufacturers. Total DNA and RNA from
neurospheres were extracted using All Prep DNA/RNA
mini kit (Qiagen, Hilden, Germany). RNA from snap fro-
zen specimens was extracted by TRIZOL® (Invitrogen,
Life technologies, Foster City CA, USA) using the manu-
facturer’s protocol. DNA and RNA concentration and
purity were measured using Nanodrop® (Thermo Scien-
tific, Pierce Biotechnology, Rockford IL, USA).
Copy number variation assay
Copy number variation assay was performed on ViiA™ 7
Real-Time PCR System (Applied Biosystems, Life tech-
nologies, Foster City CA, USA) using Taqman® copy
number assay chemistry (Applied Biosystems, Life tech-
nologies, Foster City CA, USA). Duplex real-time PCR
was performed using 5 ng/μl of DNA. FAM-labeled
assays were used for EGFR (Hs4942325_cn), HGF
(Hs04982672_cn), NFKBIA (Hs01379535_cn), HPRT1
(Hs05654996_cn) (Applied Biosystems, Life technolo-
gies, Foster City CA, USA) and VIC-labeled assay was
used for reference gene (TERT 20X, Applied Biosystems,
Life technologies, Foster City CA, USA). DNA extracted
from peripheral blood was used as control. To discrim-
inate between EGFR amplification and polysomy of
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against HGF copy number also mapping on chr7 and
usually not amplified: threshold for amplification was
EGFR/HGF copy number ratio ≥ 4.
RT-PCR and real time PCR
500 ng RNA were reverse-transcribed using the High Cap-
acity cDNA Reverse Transcription kit on 2720 Thermal
Cycler (Applied Biosystems, Life technologies, Foster City
CA, USA).
Real Time PCR was performed using Taqman® reagents
on ViiA™ 7 Real-Time PCR System (Applied Biosystems,
Life technologies, Foster City CA, USA): Taqman Univer-
sal Master Mix, EGFR assay (Hs_01076078_m1) and
GAPDH assay as calibrator (Hs_99999905_m1) (Applied
Biosystems, Life technologies, Foster City CA, USA). First-
Choice® Human Brain Total RNA was used as control
(Ambion, Life technologies, Foster City CA, USA).
Amplification of full length EGFR and EGFRvIII was
performed using Taq Gold® DNA Polymerase on 2720
Thermal Cycler (Invitrogen, Life technologies, Foster
City CA, USA). PCR conditions were as follows: 95°C for
10 min; 42 × [95°C for 30 sec, 56.5°C for 30 sec, and 72°C
for 1 min 20 sec sec]; and 72°C for 10 min. PCR products
were analyzed into a 2.0% agarose gel. The following
primers were used: EGFRvIII forward 5′-CTTCGGGGAG
CAGCGATGCGA-3′ and reverse 5′-ACCAATACCTATT
CCGTTACA-3′; wtEGFR forward 5′-CCAGTATTGATC
GGGAGAGC-3′ and reverse 5′- CCAAGGACCACCTCA
CAGTT-3′ (PRIMM, Italy).
Evaluation of NF-kB activity and IL-6 levels
Cytoplasmatic and nuclear proteins were extracted using
the Nuclear extract kit (Active Motif, Carlsbad CA, USA)
according to manufacturer’s protocol. Protein concen-
tration was measured by MicroBCA Protein Assay kit at
OD= 540 nm (Thermo Scientific, Pierce Biotechnology,
Rockford IL, USA) and analyzed using a microplate ab-
sorbance reader Multiskan FC (Thermo Scientific, Pierce
Biotechnology, Rockford IL, USA).
NF-kB activity was measured in protein extracts using
the TransAMTM NF-kB p65 protein assay (Active Motif,
Carlsbad CA, USA), an ELISA-based method in which
an oligonucleotide representing the NF-kB consensus
binding site is immobilized on 96-well plates; p65 sub-
unit is revealed by HRP-conjugated antibodies and ana-
lyzed at OD = 450 nm.
Interleukin-6 levels were measured from supernatants of
neurospheres using Human IL-6 ELISA kit 96-well plate,
based on standard sandwich enzyme-linked immune-
adsorbent technology and revealed by Avidin-Biotin-
Peroxidase Complex System (Wuhan Boster Biological
Technology, Wuhan China), according to manufacturer’s
protocol and analyzed at OD= 450 nm.Array-CGH
Array-CGH was performed using the CytoChip oligo-
array (ISCA) 180K, containing 181,873 oligonucleotide
probes (BlueGnome Ldt, Cambridge, UK) with a mean
resolution of 16.30 Kb (25 Kb resolution on the backbone,
3.4 Kb resolution on genes). Data analysis was performed
using InnoScan 710 Microarray Scanner (Innopsys Inc.
Chicago IL, USA) and Bluefuse software (BlueGnome Ldt,
Cambridge, UK). Oligo positions are referred to hg19.
One μg of sample and reference genomic DNAs were
digested and then labelled with Cy3 (samples) and Cy5
(references) fluorophores, using random primers. The la-
belled DNAs were cleaned up using Amicon Ultracel-30
membrane filters (AU-30) (Millipore, Billerica MA,
USA) followed by vacuum concentration if required.
Labelled DNAs of samples were combined with sex-
matched labeled references and then hybridized with
oligonucleotide probes of array platform. Hybridization
was performed using MaiTaiTM Hybridization System
(SciGene, Sunnivale CA, USA). After 24 hours Cyto-
Chip oligo-array was washed and scanned. Amplifica-
tions or deletions are revealed by green (Cy3) or red
(Cy5) signals, due to unbalanced ratio between the two
fluorophores.
Probes located at +0.3 and -0.3 in the hg19 are in
double copy (normal genotype); probes at +0.40 and
+0.60 are in triple copy; more than +0.60 it is referred to
gene amplification. Probes at -0.6 and 1 are in single
copy, whereas probes at -2 are nullisomic.
Immunohistochemistry
Surgical specimens are fixed in Carnoy, paraffin-embedded
and sectioned at 2 μm. Sections are mounted on slides,
paraffin removed by xylene and blocked in 10% H2O2
(Sigma-Aldrich, St. Louise, Missouri, USA). The sec-
tions are first incubated with normal goat serum
(Dako, Glostrup, Denmark) and then in a humidified
chamber with mouse monoclonal anti-EGFR (Thermo
Scientific, INC, USA). Sections are then incubated with
anti-mouse Envision® peroxidase conjugated (Dako,
Glostrup, Denmark). Finally, sections reacted with
diaminobenzidine (Liquid DAB Substrate Chromogen
System, DakoCytomation Carpinteria, CA, USA), co-
unterstained with hematoxylin and mounted.
For hematoxylin-eosin staining, slides deparaffined in
xylene are stained in Carazzi hematoxylin solution,
rinsed in running tap water and counterstain in eosin
solution.
Data analysis
The ΔΔCt method was used to determine gene ex-
pression and copy number variation; copy number var-
iation (CNV) was determined as 2(2- ΔΔCt), where 2 is
the usual copy number of a gene [24]. Numerical results
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cance (P < 0.05) was evaluated using Student t test.
Results
Clinical and histological features
Tumor samples were obtained from 69 patients (48
males) operated at the IRCCS Foundation “C.Besta”
Neurological Institute from 2007 to 2012. Mean age was
57 (range 18-78 years). 40/69 patients died after first
surgery, 14/69 were re-operated after few months: the
median survival time ranged from 9 to 12 months after
surgery. Histologically, all tumors showed features of
glioblastoma such as pleomorphic cells, microvascular
proliferation, necrotic areas and pseudo-palisades.
EGFR status in primary GBM and corresponding
neurospheres
We performed a copy number variation (CNV) assay to
assess the EGFR amplification status in 69 primary GBM
(here defined as brain tumors, BT) and in corresponding
neurospheres (here defined as NS), cultured in the pres-
ence of EGF and bFGF. To differentiate EGFR amplifica-
tion from polisomy of chromosome 7 we considered the
ratio between CNV of EGFR and HGF, both located on
chromosome 7, normalised to the reference gene TERT.
Table 1A summarizes results in brain tumors (BT)
with or without EGFR amplification and in correspond-
ing NS: EGFR was amplified in 36 tumors (52%), but
only in 23 corresponding NS (33%).
Figure 1A shows the EGFR/HGF ratio: in BT the me-
dian CNV ratio was 47; this value significantly decreased
in NS, with median CNV ratio of 10 (p < 0.001).
Thus, 13/36 BT lost EGFR amplification in corre-
sponding NS and EGFR CNV significantly decreased in
the remaining 23 NS when compared to BT values.
NFKBIA status in primary GBM and corresponding
neurospheres
We then performed the CNV assay to assess the
NFKBIA status on same BT and NS tested for EGFR
amplification. Only 3 BT showed heterozygous deletionTable 1 Summary of EGFR and NFKBIA copy number
variation in primary GBM (BT) and corresponding
neurospheres (NS)
1A EGFR wt EGFR amp % amp
BT 33 36 52%
NS 46 23 33%
1B NFKBIA wt NFKBIA+/- % del
BT 66 3 4%
NS 39 30 43%
1C EGFR wt EGFR amp loss of EGFR amplification
NFKBIA+/- NS 11 12 7of NFKBIA and this alteration was mutually exclusive
with EGFR amplification. Surprisingly, however, hete-
rozygous deletion of NFKBIA was detected in a much
larger number of cases, 30 of 69 NS lines (Table 1B).
The deletion was mutually exclusive with EGFR ampli-
fication in 18/30 NS; notably, 7/30 of these NS had lost
EGFR amplification in vitro; in the remaining 12 NS the
heterozygous deletion was present concurrently with
EGFR amplification (Table 1C).
Figure 1B displays the median copy number of NFKBIA:
combining BT and NS that we defined as hemizygously
deleted for NFKBIA the median CNV was 1.2, while in
remaining BT and NS the median CNV was 2.6.
To confirm that the CNV assay is able to distinguish
one from two copies of a gene, we performed an assay
to evaluate HPRT1 CNV on 6 controls, 3 females and 3
males: HPRT1 maps on chromosome X and therefore
one copy only is present in males. Accordingly, females
had 2 copies of the gene and males one copy only
(Additional file 1: Figure S1), confirming that the CNV
assay used to study NFKBIA detects hemizygosity.
Validation of CNV data also derived from array-CGH
experiments on four GBM: BT418, 419, 314 and
NS297. EGFR amplification on 7p11.2 (probe position
according to hg19 at +0.60) was confirmed in two
primary BT (BT418 e BT419) in which we found high
EGFR/HGF ratios (74 and 323, respectively; BT418
shown in Figure 2C). BT314 showed trisomy of chro-
mosome 7 and absence of EGFR amplification (probe
position at +0.40) in agreement with results of the
CNV assay (Figure 2A). BT314 showed NFKBIA dele-
tion in the primary tumor: this was confirmed by array-
CGH, showing complete loss of the long arm of
chromosome 14 (Figure 2B). In NS297 EGFR ampli-
fication was pinpointed by the CNV assay but not by
array-CGH, suggesting the possibility of a focal intra-
genic deletion not detectable by the CGH probes used
in this array that only flank NFKBIA.
Taken together the data confirm that the CNV assay is
able to detect gene amplifications and heterozygous
deletions of EGFR and NFKBIA, respectively.
Functional validation of NFKBIA heterozygous deletion
To validate further CNV data, we investigated the func-
tional consequences of NFKBIA deletion. We speculated
that the deletion could decrease intracellular levels of
the NF-kB inhibitor (IkB), causing increased transloca-
tion of NF-kB into the nucleus and, consequently, in-
creased transcription of target genes.
As a readout of NF-kB activity we investigated p65
subunit activation. We compared p65 activity in cyto-
plasmic and nuclear extracts of 8 NS with NFKBIA
deletion and 6 without deletion. As shown in Figure 3,
we found that p65 activity was significantly higher in
Figure 1 Copy number variation values (CNVs) in primary GBM (brain tumors, BT) and corresponding neurospheres (NS). A) EGFR
amplification in BT and corresponding NS is expressed as EGFR/HGF ratio in comparison to control DNA and shows significant loss of amplification
in vitro (**p < 0.001). B) Heterozygous deletion in BT and NS shows a median copy number value of 1.2 compared to healty DNA and not deleted lines.
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in others (p < 0.005). This observation confirms that
NFKBIA deletion in GBM NS may have relevant func-
tional consequences.
As a further readout of NF-kB activity we also mea-
sured IL-6 levels in the culture medium of NS 462 and
NS 470. This pro-inflammatory cytokine is a known
target of NF-kB transactivation. Notably, IL-6 is also
produced in EGFRvIII cells and released in the micro-
environment to activate adjacent wtEGFR cells through
GP130 activation [25]. IL-6 levels showed correlation
with the presence of the EGFRvIII variant and NFKBIA
deletion: they were present in NS 462 cells, cultured
with or without EGF and in NS 470 cells cultured in
complete medium, but were very low in the absence ofEGF, when EGFRvIII is almost absent and NFKBIA is
not deleted (Figure 4).
Characterization of NS cultured with or without EGF
Previous data showed that EGF in the culture medium
of NS may affect EGFR amplification [26]. To evaluate
the contribution of EGF in the culture medium to EGFR
amplification and /or NFKBIA expression, we established
NS cultures from primary GBMs in the presence of
either complete or modified medium (i.e. containing
both EGF and bFGF or bFGF only, respectively).
We first investigated four NS lines deriving from BT
with EGFR amplification. Figure 5 shows the comparison
of EGFR/HGF copy number ratio (Figure 5A) and
NFKBIA copy number (Figure 5B) in BT, NS in complete
Figure 2 Validation of CNV Assay by array-CGH analysis. A) Trisomy of chromosome 7, but not EGFR amplification (probe position at +0.40),
in BT314. B) Complete loss of chromosome 14q in BT314 (probe position at -0.40/-0.60); C) EGFR amplification in primary tumor BT418 (probe
position at +0.60).
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Figure 3 Functional validation of NFKBIA heterozygous deletion in NS. Comparison of p65 activity in cytoplasmatic versus nuclear proteins
in NS shows a significant (** p < 0.005) activity only in nuclear extract of NFKBIA deleted NS.
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complete medium all cell lines showed a marked de-
crease of EGFR amplification versus the corresponding
BT, with 3 to 20 folds lower levels of EGFR/HGF copy
number ratio. EGFR copy number was always higher in
the absence of EGF: although this trend was present in
all four cell lines, levels of EGFR amplification ranged
from control values in NS 459 to levels higher than
primary BT in NS 470 (Figure 5A).Figure 4 IL-6 expression in cultured cells. Quantification of IL-6 in surna
production in BT470 in complete medium where NFKBIA deletion and EGF
and EGFRvIII are shown below for comparison.Two cell lines, NS 462 and NS 470, showed heterozy-
gous loss of NFKBIA in the complete medium, not
detected in the original tumor: notably, the deletion was
absent in the modified medium.
To further investigate the EGFR status we performed a
quantitative evaluation of EGFR expression in BT and
NS 462 and 470 by Real Time PCR, and investigated by
a semi-quantitative method, RT-PCR, the presence of
wild type EGFR and EGFRvIII (Figure 6A). The probetants of NS lines cultured in different conditions shows higher IL-6
RvIII are both present (**p < 0.001). RT-PCRs displaying wild type EGFR
Figure 5 Analysis of copy number variations (CNVs) in BT and corresponding NS cultured in different conditions. A) EGFR status in NS
cultured in presence of both growth factors and in presence of bFGF only shows a strong CNV decrease in complete medium and persistence of
EGFR amplification at variable levels in absence of EGF. B) NFKBIA status in NS cultured in presence of both growth factors and in presence of
bFGF alone shows an heterozygous NFKBIA deletion in two NS cultured in complete medium: BT462 and BT470.
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EGFRvIII (see also Methods). NS 462 showed increased
presence of EGFRvIII and decreased presence of wtEGFR,
particularly in the absence of EGF. BT470, on the con-
trary, showed a strong decrease of EGFRvIII in vitro and
an increase of wtEGFR, particularly in the absence of EGF.
In Figure 6B we show H&E staining and immunohisto-
chemistry with anti-EGFR antibody of BT462 and BT470
indicating strong EGFR expression, as expected.
Two other cell lines were also considered, BT463 and
BT467 that did not show EGFR amplification or NFKBIA
loss in the original tumor. Under both culture condi-
tions (EGF plus bFGF or bFGF only) the status of these
two genes did not change, suggesting that absence of
EGF per se is not sufficient to drive EGFR amplification
(Additional file 2: Figure S2).Overall the data suggest that loss of EGFR amplifica-
tion in vitro is favored by EGF presence in the culture
medium. Clonal expansion of cells harboring NFKBIA
deletion and/or EGFRvIII deletion may take place in this
context.
Survival analysis
We looked for correlations of EGFR amplification and/
or NFKBIA deletion and overall survival (OS): four
GBM were excluded from analysis as the patients died
early after diagnosis for reasons unrelated to tumor
progression. We could not find significant correlations
between the presence of NFKBIA deletion in NS and
OS (Additional file 3: Figure S3A) also considering the
association with presence or lack of EGFR amplification
(Additional file 3: Figure S3B). EGFR amplification was
Figure 6 EGFR and EGFRvIII expression in primary BT and corresponding NS cultured in different conditions. A) The upper part shows
mRNA levels of EGFR in primary tumors and corresponding NS; the lower part shows the presence of wild type EGFR and/or the mutant EGFRvIII:
BT462 displays a gradual appearance of EGFRvIII in modified medium, whereas BT470 shows the presence of the mutant form in primary tumor
and in NS cultured in complete medium; B) Immuno-histochemistry on tumors specimens shows high levels of EGFR in both tumors.
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(Additional file 3: Figure S3C), confirming ambiguities
on the prognostic role of this marker [27].
Discussion
NFKBIA deletion is present at low frequency in primary
GBM
In this work we investigated the presence of the NFKBIA
deletion in GBM. After the report by Bredel et al [19]
one paper only reported on NFKBIA deletions in a frac-
tion of GBM but did not confirm mutual exclusivity with
EGFR amplification [28]. Recent reports based on TCGA
data did not mention a high frequency of hemizygosity
on 14q13, where NFKBIA maps [29,30].
In our work we found a 4.3% frequency of NFKBIA
deletion in 69 primary GBM. It is possible that the pres-
ence of normal cells in the surgical specimen leads to
underestimation of the number of cases with deletion:
this, however, seems plausible for a minority of cases.
Furthermore, previous work reporting loss of heterozy-
gosity on chromosome 14 showed loss of the entire q
arm as a rather frequent event and partial losses located
on 14q23-q32, telomeric to the NFKBIA locus [31,32].
It is plausible that other biological mechanisms inde-
pendent of EGFR have a major role in NF-kB activation
in GBMs. This family of transcription factors is the ob-
ject of a number of studies pointing at its therapeutic
targeting [33]. However its contribution to tumorigen-
esis in cells of neural origins needs further evaluation.
Data from murine or rat NS showed that loss of both
p65 and p50 NF-kB subunits results in a reduced num-
ber of progeny and in increased neuronal differentiation
[34] and that activation of the canonical NF-kB pathway
by TNF-alpha increases NS proliferation [35]. More recent
data, however, suggest a pro-differentiation role of NF-kB.
In murine embryonic stem cells Nanog, an essential factor
for GBM tumorigenicity [36], binds to NF-kB proteins,
inhibiting their transcriptional activity: overexpression of
NF-kB proteins promoted differentiation, whereas inhib-
ition increased expression of pluripotency markers [37].
Notably, also in GBM-NS the NF-kB transcriptional path-
way was activated in the presence of serum-driven differ-
entiation [38].
Overall, our first conclusion, based on this set of data
is that the NFKBIA deletion is present but not frequent
in primary GBM.
NFKBIA deletion in culture is favored by EGF
This observation is strengthened by the in vitro data we
gathered on GBM neurospheres (NS). Unexpectedly, we
found a large fraction of GBM NS showing results of the
copy number assay for NFKBIA compatible with a het-
erozygous deletion. In parallel we observed the dis-
appearance of EGFR amplification in part of these NSand decreased CNV values in others. Our results suggest
the possibility that NFKBIA deletions are magnified (or
created) in vitro in GBM NS that have decreased or lost
amplification of EGFR. Since EGFR signaling may also
impinge of NF-kB, as indicated by data in breast cancer
[16] and GBMs [18], it seems plausible that in tumors
“addicted” to this signaling pathway, NFKBIA deletions
arise or are selected for in the presence of loss or
decreased amplification of EGFR. The idea that part of
the NFKBIA deletions in NS are favored by culture con-
ditions and therefore do not mirror the actual situation
of the primary tumor receives some indirect support by
the lack of correlations with OS that we have found
(Additional file 3: Figure S3), differently from what
reported by Bredel et al [19].
Two sets of observations suggest that the assay we
used is appropriate for CNV studies in these cells. First,
we validated this technique by showing that HPRT1,
a gene located in chromosome X, is present with two
copies in females and one copy in males (hemizygosity).
Second, we showed that the decreased copy number of
NFKBIA has functional consequences. We expected that
decreased gene dosage of NFKBIA may cause increased
migration to the nucleus of the NF-kB transcription fac-
tor and consequent increased activity of the p65 subunit.
This was actually demonstrated in an ELISA-based test-
ing on GBM NS with or without NFKBIA deletion. A
third line of evidence was provided by array-CGH tested
on one primary tumor, where NFKBIA deletion, detected
by CNV assay, was associated to the entire loss of
chromosome 14. EGFR amplification detected by CNV
assay was also confirmed by array-CGH in these tumors
and in one GBM NS. In this latter case, the NFKBIA de-
letion detected by the CNV assay was not found by
array-CGH: we should consider, however, that the array
CGH we used contain probes hybridizing to flanking
and not intragenic regions of NFKBIA, so that hemizyg-
osity would only be detected in the presence of large
deletions or loss of the entire chromosome.
EGFRvIII may be favored in vitro by lack of EGF
The progressive lack of EGFR amplification in the pres-
ence of EGF in the culture medium is in good agreement
with data from Schulte et al, showing that EGFR amplifi-
cation is progressively lost under culture conditions used
for NS growth [26]. Notably these authors found that
EGFR amplification is associated to slower growth in vitro
and that the difference in growth is decreased/canceled if
EGF is removed from the culture medium [26]. The recent
observation that EGFR amplification is associated to
increased capacity for invasion rather than proliferation is
in agreement with this observation [39].
Another response that can be favored in vitro in the
absence of EGF-induced signaling by EGFR is the partial
Patanè et al. Molecular Cancer 2013, 12:160 Page 11 of 12
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lular domain interacting with its ligand and consequent
constitutive activation [12]. EGFRvIII may also activate
NF-kB through mTORC2 [7]: thus, this deletion, that
occurs in the majority of GBMs with EGFR amplification
[40], may also preserve the function of the EGFR-NF-kB
axis in glioma perpetuation.
Previous data by different groups including ours, have
proposed that GBM NS provide a better system than
serum-dependent cultures, to study GBM biology in vitro
and in vivo [22,23,41]. Present results, however, indicate
that presence of EGF may partially skew the molecular
signatures present in primary GBMs. This is well illus-
trated by recent data showing that TNF-mediated activa-
tion of NF-kB is stimulated by mcroglia-macrophages in
the tumor microenvironment and lost in vitro, thus favor-
ing a proneural phenotype in GBM NS [42].
In conclusion, the data we obtained indicate that
NFKBIA deletions are present but not frequent in GBMs,
at difference with the initial report by Bredel et al [19].
This information and available evidence from the lite-
rature suggest that more work is required to thoroughly
define the relevant mechanisms of NF-kB activation in
GBM.
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